QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.28 (-1.64%)
AMD   117.83 (-5.15%)
T   16.10 (+2.74%)
F   13.59 (+5.10%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.26%)
GE   106.08 (+0.59%)
DIS   92.52 (+0.39%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.28 (-1.64%)
AMD   117.83 (-5.15%)
T   16.10 (+2.74%)
F   13.59 (+5.10%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.26%)
GE   106.08 (+0.59%)
DIS   92.52 (+0.39%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.28 (-1.64%)
AMD   117.83 (-5.15%)
T   16.10 (+2.74%)
F   13.59 (+5.10%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.26%)
GE   106.08 (+0.59%)
DIS   92.52 (+0.39%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.28 (-1.64%)
AMD   117.83 (-5.15%)
T   16.10 (+2.74%)
F   13.59 (+5.10%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.26%)
GE   106.08 (+0.59%)
DIS   92.52 (+0.39%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
NASDAQ:KLDO

Kaleido Biosciences (KLDO) Stock Forecast, Price & News

Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
10,597 shs
Market Capitalization
$4,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

KLDO stock logo

About Kaleido Biosciences (NASDAQ:KLDO) Stock

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Receive KLDO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kaleido Biosciences and its competitors with MarketBeat's FREE daily newsletter.

KLDO Stock News Headlines

“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
KLDO Kaleido Biosciences, Inc.
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Kaleido Biosciences, Inc. (KLDO)
ATER, HNRG and AGLE among mid-day movers
Kaleido Biosciences shuts down
See More Headlines


KLDO Company Calendar

Last Earnings
11/01/2021
Today
6/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KLDO
Fax
N/A
Employees
76
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.10 million

Miscellaneous

Free Float
38,787,000
Market Cap
$4,000.00
Optionable
Not Optionable
Beta
-0.06

Key Executives

  • Ms. Kimberly Hocknell
    Sr. VP of Technical Operations
  • Ms. Susan Stewart J.D. (Age 62)
    L.L.M., Chief Regulatory Affairs – Advisor
  • Dr. Mark A. Wingertzahn Ph.D. (Age 51)
    Sr. VP of R&D and Head of Devel.













KLDO Stock - Frequently Asked Questions

How were Kaleido Biosciences' earnings last quarter?

Kaleido Biosciences, Inc. (NASDAQ:KLDO) issued its earnings results on Monday, November, 1st. The company reported ($0.54) EPS for the quarter, meeting the consensus estimate of ($0.54). The firm earned $0.10 million during the quarter, compared to the consensus estimate of $0.25 million.

What other stocks do shareholders of Kaleido Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Precision BioSciences (DTIL), Fulcrum Therapeutics (FULC), LogicBio Therapeutics (LOGC), Homology Medicines (FIXX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE) and Stoke Therapeutics (STOK).

When did Kaleido Biosciences IPO?

(KLDO) raised $101 million in an IPO on Thursday, February 28th 2019. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Kaleido Biosciences' stock symbol?

Kaleido Biosciences trades on the NASDAQ under the ticker symbol "KLDO."

How do I buy shares of Kaleido Biosciences?

Shares of KLDO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How much money does Kaleido Biosciences make?

Kaleido Biosciences (NASDAQ:KLDO) has a market capitalization of $0.00 and generates $1.10 million in revenue each year.

How can I contact Kaleido Biosciences?

The official website for the company is www.kaleido.com. The company can be reached via phone at (617) 674-9000.

This page (NASDAQ:KLDO) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -